Evidence map›Paper›PMID 40401900›Full record

ArticleOncoimmunology2025

Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.

Fereshteh Talebi, Fabiana Gregucci, Jalal Ahmed, Nir Ben Chetrit, Brian D Brown, Timothy A Chan, Dhan Chand, Julie Constanzo, Sandra Demaria, Dmitry I Gabrilovich and 27 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Fereshteh TalebiDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
Fabiana GregucciDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-9947-9650
Jalal AhmedIcahn Genomics Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nir Ben ChetritDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
Brian D BrownIcahn Genomics Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Timothy A ChanDepartment of Cancer Sciences, Global Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-9265-0283
Dhan ChandAgenus Inc, Lexingston, MA, USA.
Julie ConstanzoInstitut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France.
Sandra DemariaDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
Dmitry I GabrilovichAstraZeneca, Gaithersburg, MD, USA.
Encouse GoldenDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
Andrew GodkinDivision of Infection and Immunity/Systems Immunity University Research Institute, School of Medicine, Cardiff University, Cardiff, UK.
Chandan GuhaDepartments of Radiation Oncology and Pathology, Albert Einstein College of Medicine, New York, NY, USA.
Gaorav P GuptaDepartment of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Aisha HasanJohnson & Johnson, New Brunswick, NJ, USA.
Fernanda G HerreraAGORA Cancer Research Center, Swiss Cancer Center Leman, Lausanne, Switzerland.
Howard KaufmanAnkyra Therapeutics, Cambridge, MA, USA.
Donna LiUniversity of Wisconsin, Madison, WI, USA.
Alan A MelcherDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
Sierra McDonaldUNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Taha MerghoubSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Arta M MonjazebDepartment of Radiation Oncology, University of California, San Diego, CA, USA.
Sébastien ParisNanobiotix, Paris, France.
Sean PitrodaDepartment of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL, USA.
Anguraj SadanandamDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Dörthe SchaueDepartment of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Laura SantambrogioDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
Phillippe SzaparyInterventional Oncology, Johnson & Johnson, New Brunswick, NJ.
Julien SageDepartments of Genetics and Pediatrics, Stanford University, Stanford, California.
James W WelshDepartment of Radiation Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
Anna WilkinsDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
Kristina H YoungDivision of Radiation Oncology, The Oregon Clinic, Portland, OR, USA.
Eric WennerbergDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
Laurence ZitvogelGustave Roussy, INSERM U1015, Division of Medicine, Paris-Saclay University, Center of Clinical Investigations BIOTHERIS, Villejuif, France.
Lorenzo GalluzziCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Eric DeutschDepartment of Radiation Oncology, Gustave Roussy, INSERM U1030, Division of Medicine, Paris-Saclay University, RHU LySAIRI "Lymphocyte-Sparing Artificial Intelligence-guided Radio-Immunotherapy", Villejuif, France.
Silvia C FormentiDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The annual ImmunoRad Conference has established itself as a recurrent occasion to explore the possibility of combining radiation therapy (RT) and immunotherapy (IT) for clinical cancer management. Bringing together a number of preclinical and clinical leaders in the fields of radiation oncology, immuno-oncology and IT, this annual event fosters indeed essential conversations and fruitful exchanges on how to address existing challenges to expand the therapeutic value of RT-IT combinations. The 8th edition of the ImmunoRad Conference, which has been held in October 2024 at the Weill Cornell Medical College of New York City, highlighted exciting preclinical and clinical advances at the interface between RT and IT, setting the stage for extra progress toward extended benefits for patients with an increasing variety of tumor types. Here, we critically summarize the lines of investigation that have been discussed at the occasion of the 8th Annual ImmunoRad Conference.

Indexed as

ImmunotherapyNeoplasmsRadiotherapyAnimalsCombined Modality TherapyHumansAbscopal effectCAR T cellsCD8+ cytotoxic T lymphocyteslow-dose radiation therapyTREG cellstumor-associated macrophages

Identifiers

PMID40401900
PMCPMC12101595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.